Published in AJR Am J Roentgenol on October 01, 2007
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol (2011) 2.03
Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol (2009) 1.89
Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol (2009) 1.76
Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging (2013) 1.54
A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds. Rev Sci Instrum (2009) 1.42
Intravoxel incoherent motion MR imaging for prostate cancer: an evaluation of perfusion fraction and diffusion coefficient derived from different b-value combinations. Magn Reson Med (2012) 1.34
Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging (2013) 1.27
The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment. Diagn Interv Radiol (2009) 1.21
MR imaging of the prostate in clinical practice. MAGMA (2008) 1.15
Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol (2010) 1.12
Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep (2010) 1.11
Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol (2012) 1.11
Multiparametric magnetic resonance imaging of prostate cancer. Indian J Radiol Imaging (2012) 1.09
In vivo optical imaging and dynamic contrast methods for biomedical research. Philos Trans A Math Phys Eng Sci (2011) 1.08
Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation. Eur Radiol (2011) 1.05
Multidisciplinary functional MR imaging for prostate cancer. Korean J Radiol (2009) 1.04
Imaging of tumor angiogenesis: functional or targeted? AJR Am J Roentgenol (2009) 1.00
Can quantitative dynamic contrast-enhanced MRI independently characterize an ovarian mass? Eur Radiol (2010) 1.00
New horizons in prostate cancer imaging. Eur J Radiol (2008) 0.99
The histogram analysis of diffusion-weighted intravoxel incoherent motion (IVIM) imaging for differentiating the gleason grade of prostate cancer. Eur Radiol (2014) 0.97
Decision support system for localizing prostate cancer based on multiparametric magnetic resonance imaging. Med Phys (2012) 0.96
The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int (2013) 0.94
Multiparametric magnetic resonance imaging of the prostate: current concepts. Radiol Bras (2015) 0.92
Functional MRI for radiotherapy dose painting. Magn Reson Imaging (2012) 0.92
Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy. Biomed Res Int (2014) 0.89
MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nat Rev Urol (2010) 0.88
PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. Contemp Clin Trials (2015) 0.87
Incremental learning with SVM for multimodal classification of prostatic adenocarcinoma. PLoS One (2014) 0.86
Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights. MAGMA (2011) 0.85
Functional and molecular imaging of localized and recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.83
Functional MRI in prostate cancer detection. Biomed Res Int (2014) 0.83
Quantitative analysis of 3-Tesla magnetic resonance imaging in the differential diagnosis of breast lesions. Exp Ther Med (2014) 0.81
Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. Magn Reson Imaging (2015) 0.81
Imaging aspects of the tumor stroma with therapeutic implications. Pharmacol Ther (2013) 0.81
Prediction and monitoring of the response to chemoradiotherapy in oral squamous cell carcinomas using a pharmacokinetic analysis based on the dynamic contrast-enhanced MR imaging findings. Eur Radiol (2011) 0.79
The role of MRI in prostate cancer active surveillance. Biomed Res Int (2014) 0.79
The principal of dynamic contrast enhanced MRI, the method of pharmacokinetic analysis, and its application in the head and neck region. Int J Dent (2012) 0.77
Feasibility of multiparametric prostate magnetic resonance imaging in the detection of cancer distribution: histopathological correlation with prostatectomy specimens. Prostate Int (2014) 0.77
Development and evaluation of a multichannel endorectal RF coil for prostate MRI at 7T in combination with an external surface array. J Magn Reson Imaging (2015) 0.77
Precision analysis of kinetic modelling estimates in dynamic contrast enhanced MRI. MAGMA (2011) 0.77
Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer. J Clin Imaging Sci (2016) 0.76
Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. Insights Imaging (2016) 0.76
Evaluation of optimized magnetic resonance perfusion imaging scanning time window after contrast agent injection for differentiating benign and malignant breast lesions. Exp Ther Med (2017) 0.75
Differential diagnosis of prostate cancer and noncancerous tissue in the peripheral zone and central gland using the quantitative parameters of DCE-MRI: A meta-analysis. Medicine (Baltimore) (2016) 0.75
A Patient with Anterior, Apical, Transitional Zone Prostate Cancer Missed Twice by Standard Biopsy. Eurasian J Med (2017) 0.75
Application of an unsupervised multi-characteristic framework for intermediate-high risk prostate cancer localization using diffusion-weighted MRI. Magn Reson Imaging (2016) 0.75
Computer aided diagnosis of prostate cancer: A texton based approach. Med Phys (2016) 0.75
Improved performance of prostate DCE-MRI using a 32-coil vs. 12-coil receiver array. Magn Reson Imaging (2017) 0.75
In vivo detection of the effects of preconditioning on LNCaP tumors by a TNF-α nanoparticle construct using MRI. NMR Biomed (2014) 0.75
PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER. Expert Rev Precis Med Drug Dev (2016) 0.75
Feasibility study of CT perfusion imaging for prostate carcinoma. Eur Radiol (2014) 0.75
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) (2008) 4.08
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years. Ann Intern Med (2008) 3.34
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol (2013) 2.62
Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol (2012) 2.59
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res (2009) 2.51
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg (2008) 2.39
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Crash and risky driving involvement among novice adolescent drivers and their parents. Am J Public Health (2011) 2.25
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res (2007) 2.21
Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging (2009) 2.21
MRI of tumor angiogenesis. J Magn Reson Imaging (2007) 2.19
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol (2011) 2.10
In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res (2007) 2.01
Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer (2013) 1.97
Assessing surrogates as trial endpoints using mixed models. Stat Med (2005) 1.94
Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol (2009) 1.89
Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int (2007) 1.86
The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol (2007) 1.84
Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett (2006) 1.80
The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiol Biomarkers Prev (2007) 1.80
Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat (2004) 1.78
Differences in risk factors for recurrent versus incident preterm delivery. Am J Epidemiol (2015) 1.78
Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res (2007) 1.76
Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol (2009) 1.76
Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med (2002) 1.74
Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res (2010) 1.74
Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74
Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control (2003) 1.73
Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano (2007) 1.70
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Radiologic manifestations of Proteus syndrome. Radiographics (2004) 1.66
In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia (2007) 1.65
The effects of payment method on clinical decision-making: physician responses to clinical scenarios. Med Care (2004) 1.65
A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate. Cancer Res (2007) 1.64
H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol (2009) 1.56
Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano (2012) 1.56
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst (2004) 1.55
In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther (2009) 1.55
Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem (2012) 1.55
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res (2009) 1.53
Comparison of robotic versus laparoscopic skills: is there a difference in the learning curve? Urology (2002) 1.50
Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab (2011) 1.50
Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm (2005) 1.48
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol (2006) 1.46
Imaging of the lymphatic system: new horizons. Contrast Media Mol Imaging (2006) 1.46
An enzymatically activated fluorescence probe for targeted tumor imaging. J Am Chem Soc (2007) 1.46
Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol (2007) 1.43
Clinicopathologic implications of hMSH2 gene expression and microsatellite instability in prostate cancer. Cancer Biol Ther (2002) 1.43
A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging (2007) 1.43
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int (2012) 1.42
A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds. Rev Sci Instrum (2009) 1.42
Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm (2009) 1.42
Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers. Mol Pharm (2008) 1.39
Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies. Radiology (2013) 1.39
Laparoscopic management of ureteropelvic junction obstruction in patients with upper urinary tract anomalies. J Urol (2004) 1.39
A self-quenched galactosamine-serum albumin-rhodamineX conjugate: a "smart" fluorescent molecular imaging probe synthesized with clinically applicable material for detecting peritoneal ovarian cancer metastases. Clin Cancer Res (2007) 1.38